CBIO
Crescent BiopharmaDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
Crescent has a funded oncology pipeline, ASCEND is already underway, CR-002 is targeting an IND in mid-2026, and management says cash should fund operations into 2028 after the $185 million private placement, giving it a real window to reach several clinical inflection points [#PR-2026-02-26].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +14.2.
What can break
Cash runway is stated into 2028, but sustained high R&D burn and a pre-revenue model still leave financing risk if timelines slip.
Momentum
11
Value
41
Sentiment
67
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $18.00 · Bull $30.00 · Bear $10.00
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $29.50
Why
Momentum11 · Δ7d -7.3
Value41 · Δ7d +0.0
Sentiment67 · Δ7d +14.2
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
11
26% active weight
Current posture
7d trendSoftening
Δ7d
-7.3
Δ21d
-25.1
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
67
34% active weight
Current posture
7d trendImproving
Δ7d
+14.2
Δ21d
+23.3
Why this grade
Composite grade D. Momentum 11.2 / Value 41.1 / Sentiment 67.2
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$414.96M
Beta
1.34
Shares Out
35.67M
P/E (TTM) · Derived
-0.8
P/S (TTM)
-
P/FCF (TTM) · Derived
-1.37
Rev YoY
-100.0%
EPS YoY
-96.1%
Gross Margin
+98.8%
Op Margin
-422973.5%
Net Debt
-$211.55M
Current Ratio
13.78
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology